Motif’s (LON:MTFB) Buy Rating Reaffirmed at Northland Capital Partners

Motif (LON:MTFB)‘s stock had its “buy” rating reaffirmed by equities researchers at Northland Capital Partners in a research note issued on Tuesday, March 20th.

MTFB has been the subject of a number of other research reports. Northland Securities reaffirmed a “buy” rating on shares of Motif in a research report on Tuesday, January 16th. Peel Hunt reaffirmed a “buy” rating and set a GBX 107 ($1.51) price objective on shares of Motif in a research report on Wednesday, January 10th. Finally, FinnCap reaffirmed a “buy” rating and set a GBX 100 ($1.41) price objective on shares of Motif in a research report on Wednesday, November 22nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of GBX 101.50 ($1.43).

How to Become a New Pot Stock Millionaire

MTFB stock traded up GBX 0.35 ($0.00) during mid-day trading on Tuesday, reaching GBX 34.10 ($0.48). The company’s stock had a trading volume of 210,594 shares, compared to its average volume of 400,302. Motif has a fifty-two week low of GBX 23.50 ($0.33) and a fifty-two week high of GBX 51.75 ($0.73).

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Macon Daily and is owned by of Macon Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://macondaily.com/2018/04/12/motif-bios-mtfb-buy-rating-reaffirmed-at-northland-capital-partners-updated-updated-updated.html.

Motif Company Profile

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.

Analyst Recommendations for Motif (LON:MTFB)

Receive News & Ratings for Motif Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply